Scholars advocate molecular staging, such as through immunohistochemistry, for all colon cancers as well as detection of mismatch repair defects (MMR-D) or microsatellite instability high (MSI-H) through polymerase chain reaction to screen for Lynch syndrome and mutations in KRAS, NRAS, and BRAF in metastatic colorectal cancer (Biller and Schrag, 2021). This evidence concerns the gene KRAS and Lynch syndrome.